AMENDMENT NUMBER ONE TO DEVELOPMENT AND LICENSE AGREEMENT BETWEEN ELI LILLY AND COMPANY AND ISIS PHARMACEUTICALS, INC.Development and License Agreement • August 14th, 2003 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
Contract Type FiledAugust 14th, 2003 Company IndustryThis Amendment Number One (the "Amendment") to the Development and License Agreement between Eli Lilly and Company ("Lilly") and ISIS Pharmaceuticals, Inc. ("ISIS"), effective August 14, 2001 (the "Agreement") is made effective as of June 5, 2003.
WAIVER AND RELEASE AGREEMENTWaiver and Release Agreement • August 14th, 2003 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 14th, 2003 Company Industry JurisdictionThis Waiver and Release Agreement (the "Release") is made and entered into effective as of June 5, 2003 between Eli Lilly and Company, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 ("Lilly"), and Isis Pharmaceuticals, Inc., having its principal place of business at Carlsbad Research Center, 2292 Faraday Avenue, Carlsbad, CA 92008 ("Isis").
QuickLinks -- Click here to rapidly navigate through this documentSeverance Agreement • August 14th, 2003 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • California
Contract Type FiledAugust 14th, 2003 Company Industry JurisdictionIsis Pharmaceuticals, Inc. ("Isis") is pleased to offer you certain severance benefits in light of your contribution to Isis. As Isis has no policy or procedure requiring such benefits, we request that you keep the terms and conditions of this letter agreement confidential.
INITIAL COLLABORATION AGREEMENTInitial Collaboration Agreement • August 14th, 2003 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 14th, 2003 Company Industry JurisdictionTHIS INITIAL COLLABORATION AGREEMENT ("Agreement") is made and entered into effective as of June 23, 2003 (the "Effective Date"), by and between Industrial Technology Research Institutes ("ITRI"), located at 195 Chung-Hsing Road, Sec. 4, Chutung, Hsinchu, Taiwan 310, R.O.C., and ISIS PHARMACEUTICALS, INC., having principal offices at 2292 Faraday Avenue, Carlsbad CA 92008 ("Isis"). ITRI and Isis each may be referred to herein individually as a "Party," or collectively as the "Parties."